FeesSafety
Pluang+

Nyxoah targets 30% OSA device market by 2027 with Genio implant, projecting strong growth and undervaluation.

Market News
05 Oct 2026, 14:21 WIB
Seeking Alpha
View Source
Bullish
Nyxoah targets 30% OSA device market by 2027 with Genio implant, projecting strong growth and undervaluation.

Nyxoah, a small medical device company, is entering a growth phase with its Genio implant targeting the Obstructive Sleep Apnea (OSA) market. The company aims to capture 30% of the OSA device market by 2027, contingent on FDA approval for an expanded patient label. Revenue is projected to reach €36 million in 2026, a 260% increase year-over-year, supported by growth in trained surgeons and active accounts. Despite risks like patent litigation and management changes, the stock is considered undervalued with a potential 700% upside based on discounted cash flow analysis.

Nyxoah, a medical device company, is noted here with Pluang's health sector data for context. For readers following health stocks, 41 of 100 US health-sector stocks rose and 41 fell on Pluang today. Notable movers include FLNA at USD 0.95 (+2.04%), TWST at USD 192.03 (+1.78%), and INO at USD 1.18 (+1.72%). Data as of Oct 05, 2026 18:12 WIB.

More News

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology reported a record $69.5 million in revenue for Q3 2026, driven by expanding AI infrastructure projects and hardware deliveries. The company reduced unbilled contract assets by over 50%, improving liquidity as it shifts focus from s...

Company Fundamentals
Bullish
28 minutes ago
Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway has not sold any Apple shares in 2026, even as Apple's stock price rose 29% and its price-to-earnings ratio neared 40, indicating less concern about valuation. This decision reflects confidence in Apple's strong business fundamenta...

Market News
Bullish
32 minutes ago
US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

The U.S. government is investing $1.6 billion to develop a domestic rare-earth supply chain, aiming to reduce reliance on China. USA Rare Earth is a key player, using the funds to build out mining and processing capabilities, including developing the...

Market News
Bullish
37 minutes ago
Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences increased its full-year 2026 revenue guidance to $121-$123 million, fueled by strong demand for consumables from biopharmaceutical clients who now represent 49% of Q3 revenue. The company’s NULISA platform was selected by the U.K. ...

Company Fundamentals
Bullish
37 minutes ago
CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell updated its full-year 2026 revenue guidance to $115 million to $117 million, driven by increased usage per hospital account and expansion by 35 new hospital accounts. The company improved its gross margin to 90% from 88% last year, supported...

Company Fundamentals
Bullish
37 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App